Noopept

What is Noopept?

Noopept (omberacetam, originally coded GVS-111) is a synthetic compound developed at the Zakusov Institute of Pharmacology in Russia. Strictly speaking it is not a peptide. It is a dipeptide-derived molecule in the racetam family, but it almost always shows up in peptide nootropic stacks, which is why it lives here. It is approved in Russia as a prescription nootropic and is popular in Western cognitive-enhancement circles, where it is sold as a research chemical.

How Noopept works

Noopept is orally active and clears the blood fast, with a half-life of only minutes in rodents, but it is partly converted to cycloprolylglycine, a longer-lasting metabolite that appears to carry much of the effect. Proposed mechanisms from preclinical work include positive allosteric modulation of AMPA receptors, increased expression of nerve growth factor (NGF) and BDNF, and protection of neurons against glutamate toxicity and oxidative stress. Notably, in cell studies it blunted glutamate toxicity where piracetam did not.

What the research shows

The strongest human evidence is a Russian comparative trial by Neznamov and Teleshova in patients with mild cognitive impairment from vascular or traumatic brain disease. Noopept at roughly 20 mg per day performed comparably to piracetam over about eight weeks, at a far lower dose. The catch is familiar: the trial was open-label, run in Russia, and modest in size, and the benefit was strongest in people who already had cognitive deficits. Evidence that it helps healthy users is much weaker, and most of the mechanism data is animal work.

Dosage and how it is used

There is no FDA-approved dose. It is taken orally, and community protocols commonly cite 10 to 30 mg per day split across the day, roughly matching the Russian clinical range. These figures come from practice and Russian trials rather than modern dose-finding studies, so treat them as convention, not settled medicine.

→ How to reconstitute Noopept: calculator, units to draw & storage

Side effects and safety

Noopept is generally reported as well tolerated at the usual doses. In the clinical trial the reported adverse effects were mild and affected a minority of patients, including things like sleep disturbance, irritability, and modest blood-pressure changes. Long-term human safety data outside Russian clinical use is limited, and because it is sold as a research chemical elsewhere, product quality and purity are real variables.

• Orally active and effective at low doses, unlike most compounds in the peptide stacks it joins.
• Human benefit is clearest in people with existing cognitive deficits, not confirmed in healthy users.
• Not FDA-approved. Legal status varies by jurisdiction. Verify current status independently.

Frequently asked questions

References

• Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in mild cognitive disorders of vascular and traumatic origin. Neuroscience and Behavioral Physiology, 2009.
• Noopept. Cognitive Vitality, Alzheimer's Drug Discovery Foundation.